Details for Patent: 9,198,892
✉ Email this page to a colleague
Which drugs does patent 9,198,892 protect, and when does it expire?
Patent 9,198,892 protects VASCEPA and is included in one NDA.
This patent has twenty patent family members in ten countries.
Summary for Patent: 9,198,892
| Title: | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
| Abstract: | Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI. |
| Inventor(s): | Yokoyama; Mitsuhiro (Kobe, JP), Origasa; Hideki (Toyama, JP), Matsuzaki; Masunori (Ube, JP), Matsuzawa; Yuji (Takarazuka, JP), Saito; Yasushi (Chiba, JP), Ishikawa; Yuichi (Kobe, JP), Oikawa; Shinichi (Tokyo, JP), Sasaki; Jun (Fukuoka, JP), Hishida; Hitoshi (Nagoya, JP), Itakura; Hiroshige (Tokyo, JP), Kita; Toru (Kyoto, JP), Kitabatake; Akira (Nara, JP), Nakaya; Noriaki (Tokyo, JP), Sakata; Toshiie (Fukuoka, JP), Shimada; Kazuyuki (Utsunomiya, JP), Shirato; Kunio (Sendai, JP) |
| Assignee: | MOCHIDA PHARMACEUTICAL CO., LTD. (Tokyo, JP) |
| Application Number: | 13/672,405 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,198,892
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-001 | Jul 26, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY | ⤷ Sign Up | |||
| Amarin Pharms | VASCEPA | icosapent ethyl | CAPSULE;ORAL | 202057-002 | Feb 16, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,198,892
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-200503 | Jul 8, 2005 |
International Family Members for US Patent 9,198,892
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | PI0613704 | ⤷ Sign Up | |||
| Canada | 2570763 | ⤷ Sign Up | |||
| China | 101217952 | ⤷ Sign Up | |||
| China | 102526733 | ⤷ Sign Up | |||
| European Patent Office | 1790339 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
